Table 1.
Characteristics | Overall (n = 42) |
---|---|
Age, mean (SD), (years) | 60 (12) |
Males, no. (%) | 31 (74) |
MND subtype, no. (%) | |
ALS | 39 (93) |
PMA | 3 (7) |
PLS | 0 (0) |
Bulbar onset, no. (%) | 7 (17) |
Symptom duration (months) | |
Median | 25 |
Range | 7–218 |
Diagnostic delay (months) | |
Median | 8 |
Range | 2–130 |
Riluzole use, no. (%) | 30 (75) |
Body mass index, mean (SD), (kg/m2) | 25 (3) |
ALSFRS-R total score, mean (SD) | 36 (8) |
ΔFRS (points per month) | |
Median | 0.34 |
Range | 0.05–1.24 |
Prognostic subgroup, no. (%) | |
Very long | 16 (38) |
Long | 14 (33) |
Intermediate | 11 (26) |
Short | 1 (2) |
Very short | 0 (0) |
MND motor neuron disease, ALS amyotrophic lateral sclerosis, PMA progressive muscular atrophy, ALSFRS-R revised ALS functional rating scale, ΔFRS 48—ALSFRS-R score/disease duration [11]